Neuraxis Inc. Common Stock (NRXS)

FairStock Score: 26/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I am a patient seeker of durable value, and Neuraxis does not yet pass my basic tests. It sells neuromodulation devices for chronic pain and digestive conditions, but it has not earned a profit in any of the last four years. Revenue is moving the right way: fiscal 2025 revenue was $3.6 million versus $2.7 million in fiscal 2024, and fiscal Q2 2026 revenue was $1.9 million versus $894,086 in fiscal Q2 2025. Yet the company still lost $2.1 million in fiscal Q2 2026, after losing $7.8 million in fiscal 2025 and $8.2 million in fiscal 2024. Those are filing-based facts, and they show growth without self-funding economics. At the 2026-10-13 close of $6.50, the market capitalization was $81.6 million. FairStock's calculations show a negative P/E of -8.55, P/B of 12.04, ROE of -139.76%, and trailing free cash flow of -$5.7 million, a -7.0% FCF yield. The low D/E of 0.04 and Altman Z-Score of 5.51 suggest leverage is not the immediate problem, but FairStock's Piotroski F-Score of 4/9 and FairStock Score of 26/100 point to fragility. The Lynch screen finds no category because of four years of losses. A moat is unproven in a 24-employee med-tech firm with a narrow product line. The growth is real, but the price already assumes much future success. I would want evidence of shrinking losses and positive cash generation before calling this a bargain.

In plain English: NeurAxis makes medical devices that use mild electrical signals to treat long-term pain and digestive problems, mainly in children. Sales are growing, but the company still loses money and spends more cash than it brings in, so the business looks weak on profits. At $6.50, the stock looks expensive compared with today's sales and losses; investors are paying for hoped-for future growth.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer